We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
CSPC Pharmaceutical Group Limited | TG:CVG | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.019 | 3.08% | 0.6366 | 0.6106 | 0.6404 | 0.6366 | 0.602 | 0.602 | 1,676 | 17:18:11 |
DOW JONES NEWSWIRES
Convergys Corp. (CVG) said first-quarter net income fell 22% on a slump in sales at its information-management business.
In December, Moody's Investors Service cut Covergys' ratings to junk, saying its human-resources management business was weak and it needed to sign big contracts.
President and Chief Executive David Dougherty said the company's customer-management segment was a source of profitability. He added the company was expanding its delivery footprint.
The provider of integrated billing, employee care and customer-care services posted net income of $28 million, or 23 cents a share, from $35.9 million, or 28 cents a share, a year earlier. The previous year's results included $14.1 million in restructuring charges and $7.1 million in retirement-related expenses.
Revenue decreased 3% to $694.7 million.
Analysts surveyed by Thomson Reuters expected 20 cents a share in earnings on $695 million in revenue.
Gross margin rose to 36.2% from 234.1.
Revenue from the company's largest segment, customer management, rose 9% as operating margins rose to 7.8% from 4.6%. Sales at its information-management business fell 34% on project completions and expected client migrations in North America. Operating margins fell to 11.6% from 18.1% last year.
The company affirmed its full-year earnings guidance from January of 90 cents to $1.10 a share.
The stock closed Monday at $9.67 and wasn't active premarket. Convergys' stock price fell to an all-time low in November but has since doubled in value.
-By Joan E. Solsman and Kerry E. Grace, Dow Jones Newswires; 201-938-5500; joan.solsman@dowjones.com
1 Year CSPC Pharmaceutical Chart |
1 Month CSPC Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions